Buy Lodonak (Generic Naltrexone) Online — Affordable Opioid Receptor Antagonist for Alcohol & Opioid Use Disorder

Lodonak is a brand name for naltrexone hydrochloride, manufactured by Macleods Pharmaceuticals, one of India's largest pharmaceutical companies. The active ingredient is the same molecule found in branded ReVia, generic naltrexone, and other naltrexone products worldwide. Lodonak is widely used for the treatment of alcohol use disorder (AUD) and opioid use disorder (OUD), working through a fundamentally different mechanism than disulfiram - reducing the rewarding effects of these substances rather than creating an aversive reaction.

Key features of Lodonak

What makes Lodonak distinctive

Understanding Lodonak begins with understanding Macleods Pharmaceuticals - one of India's largest privately-held pharmaceutical companies and a major contributor to global generic medication access. Founded in 1989, Macleods has grown into a globally recognised manufacturer with WHO-GMP and US-FDA approved facilities. Lodonak reflects Macleods' broader commitment to producing essential medications at accessible prices.

Macleods milestones

Why this matters for Lodonak users

Both alcohol use disorder and opioid use disorder are global health crises affecting hundreds of millions of people. Yet medication-based treatment remains unavailable to most who could benefit, due to cost, distribution gaps, or absence of approved options in their region. Lodonak helps close this gap, bringing naltrexone treatment within financial and practical reach across India, developing markets, and for cost-conscious patients worldwide.

Regional access through Lodonak

Cost perspective (illustrative)

Approximate monthly costs for naltrexone 50 mg daily from different sources.

Indicative only. Actual pricing varies considerably by region, pharmacy, and insurance coverage.

Patients researching AUD treatment often compare naltrexone (Lodonak) and disulfiram (Antabuse, Carnotol). These medications have fundamentally different mechanisms, goals, and patient populations. Understanding the difference is essential - they are not interchangeable, and they treat AUD through opposite approaches.

The core mechanism difference

Detailed comparison

Lodonak works by blocking mu-opioid receptors in the brain. This single, precise molecular mechanism explains why naltrexone reduces alcohol craving, blocks the effects of opioids, and works for both AUD and OUD. The pharmacology is well-studied and represents one of the cleanest examples of mechanism-based pharmacotherapy in addiction medicine.

The endorphin connection

Pharmacokinetic profile

Receptor selectivity

The most common use of Lodonak is treatment of alcohol use disorder (AUD). Naltrexone is one of three FDA-approved AUD medications and arguably the most widely prescribed today, particularly in the United States. Its evidence base spans 40+ years of clinical use including landmark trials demonstrating efficacy across diverse populations.

Clinical effects in AUD

Two treatment approaches with naltrexone

Evidence highlights

Beyond AUD, Lodonak is also approved for opioid use disorder (OUD). In this role, naltrexone blocks opioid receptors so completely that taking opioids produces no effect - no euphoria, no pain relief, no respiratory depression. This makes it useful for maintaining abstinence after detoxification, but it carries critical safety requirements that differ entirely from naltrexone's AUD use.

How Lodonak works for OUD

OUD vs AUD - key differences

When Lodonak fits OUD treatment

The Sinclair Method is a specific approach to using naltrexone for AUD that emphasises reduced drinking rather than total abstinence as the primary goal. Developed by Finnish researcher Dr. David Sinclair, it uses pharmacological extinction - the gradual unlearning of drinking habits when the reward is consistently blocked. The method has gained substantial support, particularly in Europe.

How to do the Sinclair Method

Sinclair Method vs daily naltrexone

Does it work?

As with any medication, patient selection significantly affects Lodonak outcomes. Naltrexone works better for certain AUD/OUD profiles than others. Understanding who benefits most - and who is less likely to benefit - helps providers and patients make appropriate treatment choices.

Good fit vs poor fit

Patient profile types where Lodonak particularly helps

Lodonak dosing is straightforward and identical to other naltrexone products. The standard adult dose is 50 mg once daily. Some patients use lower doses (25 mg) initially or for sensitivity reasons. Higher doses (100 mg) are sometimes used in specific situations but offer marginal additional benefit. The medication is taken with or without food at a consistent time each day.

When to use lower or modified doses

When to take Lodonak

Practical daily-use rules

The single most critical safety requirement for starting Lodonak is being completely opioid-free. Starting naltrexone while opioids are still present in the body precipitates immediate, severe withdrawal - a medically dangerous reaction that requires emergency care. Both patients and providers must understand and respect this requirement absolutely.

Required opioid-free periods

Pre-treatment screening

If precipitated withdrawal occurs

Lodonak has a relatively quick onset and short residual effect compared to disulfiram. Naltrexone reaches peak plasma levels within an hour, blocks receptors within 1-2 hours, and most effects resolve within 1-3 days of stopping. Understanding this timeline helps patients plan around medical procedures, surgery, and any need to stop treatment.

The Lodonak timeline at a glance

How Lodonak compares to other AUD medications

Practical scenarios

One of the most well-documented limitations of oral naltrexone is adherence. Real-world adherence to daily oral medication for AUD averages only 30-50% over months, and naltrexone specifically faces additional adherence challenges - patients can feel "fine" without it, removing daily reminder of the problem the medication addresses. Understanding adherence challenges helps build strategies to overcome them.

Adherence reality with oral naltrexone

Why oral naltrexone is hard to stay on

Strategies to improve adherence

Vivitrol is the brand name for extended-release injectable naltrexone - approved by the FDA in 2006 for OUD and 2010 for AUD. Lodonak is the daily oral form; Vivitrol is the same molecule reformulated as a monthly injection. Choosing between them is a meaningful decision affecting adherence, cost, and clinical strategy.

Side-by-side

Detailed comparison

Common questions

Lodonak by itself is not enough. The strongest evidence for naltrexone treatment - including the landmark NIAAA COMBINE Study - consistently shows that medication combined with counseling outperforms medication alone. The pharmacological effect (reduced craving and reduced reward) enables sustained behavior change; counseling builds the skills that enable that change to last.

Evidence-based counseling approaches

Mutual support groups

How counseling and medication work together

Lodonak side effects fall into two patterns: short-term effects during the first few days to weeks (typically mild and self-limiting), and longer-term effects that may persist or develop during ongoing use. Most patients tolerate Lodonak well; serious side effects are uncommon but require attention when they occur.

Prevalence of common Lodonak side effects

Approximate frequency from clinical experience with naltrexone.

Side effects by category

This section focuses on the day-to-day side effects most Lodonak patients may notice. Most are mild, develop early in treatment, and improve as the body adapts. Understanding each one - what it feels like, why it happens, and what helps - prevents unnecessary worry and supports adherence.

Common day-to-day side effects

When to call vs manage at home

Side effect resolution timeline

Beyond the common side effects, Lodonak can occasionally cause less frequent but more serious reactions. These rare effects make periodic monitoring (especially liver function tests) and patient awareness of warning symptoms important. This section catalogues the less common and rare side effects and their warning signs.

Less common side effects (1-3%)

Rare side effects (<1%)

Warning signs - call provider immediately

Lodonak is contraindicated in several specific conditions where the risk of taking the medication outweighs the benefit. Absolute contraindications mean the medication must not be used. Relative contraindications mean special caution, additional monitoring, or alternative treatments should be considered. Pre-treatment screening for these is part of safe Lodonak prescribing.

Absolute contraindications

Lodonak must NOT be prescribed if any of the following apply.

Relative contraindications

Use only with caution; additional monitoring; alternatives often preferred.

Pre-treatment screening checklist

Like many medications metabolised by the liver, Lodonak can occasionally affect liver function. Hepatotoxicity is the most clinically significant rare adverse effect. While severe liver injury is uncommon at therapeutic doses (estimated 1-2% of patients), the risk is real - and historically there was an FDA black-box warning at one time. This makes pretreatment LFT baseline, periodic monitoring, and patient awareness of warning symptoms essential.

Understanding your LFTs

Standard LFT monitoring schedule

Warning signs of liver injury

Risk factors for hepatotoxicity

Lodonak (naltrexone) is generally avoided during pregnancy. While naltrexone has not been definitively shown to cause birth defects in humans, safety data are limited. The risk-benefit analysis depends heavily on the indication - AUD vs OUD have different considerations during pregnancy. Specialist consultation is appropriate for any pregnant patient considering naltrexone.

Trimester considerations

AUD vs OUD pregnancy considerations

Pre-conception planning

Lodonak use during breastfeeding is not generally recommended. Naltrexone and its metabolites pass into breastmilk, and infant safety data are limited. For breastfeeding mothers requiring AUD or OUD treatment, alternative approaches that allow continued safe breastfeeding are preferred when possible.

Common questions about Lodonak & breastfeeding

Alternatives during breastfeeding

If choosing to wean for Lodonak treatment

Older adults (typically 65 and over) require special considerations when using Lodonak. Age-related changes in liver and kidney function, increased side effect sensitivity, higher likelihood of cardiovascular comorbidity, and frequent polypharmacy all affect how the medication should be used. With appropriate adjustments, naltrexone can be used safely in this age group, but the threshold for caution is lower than in younger patients.

Why aging matters for Lodonak

Several physiological changes that come with age affect how Lodonak works in the body. Hepatic clearance declines, meaning naltrexone metabolites can accumulate at standard doses. Renal function reduces, slowing elimination. Older adults are also more sensitive to side effects from many medications - what feels mild in a 40-year-old can feel disruptive in someone over 70.

The other major consideration is polypharmacy. The average older adult takes five or more medications, creating more chances for drug interactions with Lodonak. A thorough medication review before starting is even more important than in younger patients.

Slower titration and closer monitoring during the first few weeks help catch any tolerability issues early. If 25 mg is well tolerated for 2-4 weeks, increase to 50 mg only if clinical response is inadequate at the lower dose.

Common challenges in older adults

Monitoring should be more frequent than in younger patients. Liver function tests every 1-2 months during the first six months of treatment, then quarterly long-term. Many older adults benefit from family or caregiver involvement in monitoring for new side effects they may not report on their own.

Both liver and kidney function affect Lodonak metabolism and elimination. The liver metabolises naltrexone into its active metabolite (6-beta-naltrexol); the kidneys excrete both. Patients with impaired organ function need adjusted dosing, more intensive monitoring, or in severe cases avoidance of Lodonak altogether. This section provides practical guidance for the spectrum of organ impairment encountered in clinical practice.

Liver impairment

Hepatic impairment is the most common organ-function consideration with Lodonak. The clinical approach depends on severity, ranging from standard dosing in mild liver disease to absolute contraindication in decompensated cirrhosis.

For patients with mild liver concerns, more frequent monitoring usually allows safe use. The earlier any worsening of liver function is detected, the more reversible it tends to be. Moderate impairment should prompt specialist consultation before starting Lodonak - sometimes the AUD severity justifies cautious use, sometimes alternatives are clearly preferable.

Kidney impairment

Naltrexone is primarily renally excreted. Kidney function affects how quickly the medication and its metabolites clear from the body. Significant renal impairment can cause accumulation and increased side effects at standard doses.

Even normal-for-age kidney function in older adults clears medications more slowly than in younger adults. This is one reason older patients often do well on 25 mg long-term rather than progressing to 50 mg.

Decision approach for impaired patients

When organ impairment is present, the question becomes whether the benefit of Lodonak outweighs the increased risk. For severe alcohol or opioid use disorder where untreated substance use is causing ongoing harm, the answer is often yes - but only with appropriate dose reduction and monitoring. For mild AUD where behavioral approaches alone might suffice, the safer path may be to skip naltrexone entirely.

Specialist consultation is the right approach for any uncertain situation. Hepatology, nephrology, or both can help determine whether the impairment is stable enough to permit cautious Lodonak use.

Alcohol and opioid use disorders commonly co-occur with other mental health conditions: depression, anxiety, PTSD, bipolar disorder, and others. Lodonak can be used in patients with mental illness, but the underlying psychiatric condition must be stable and adequately treated first. Active psychosis or untreated severe mental illness are contraindications to starting naltrexone.

The stability principle

Mental health stability before starting Lodonak is the fundamental requirement. The medication requires consistent adherence, judgment about avoiding alcohol exposure or opioid relapse, and engagement with treatment - all of which are impaired during acute psychiatric instability. The general rule is to treat the psychiatric condition first, then add Lodonak once stable.

This does not mean dual diagnosis patients are excluded from naltrexone treatment. Quite the opposite - most AUD and OUD patients have at least one co-occurring mental health condition, and naltrexone is an important treatment option. The key is timing and coordination of care.

Condition-by-condition compatibility

Coordination of psychiatric and addiction care

Both providers - the psychiatric specialist and the addiction medicine provider - need to know what the other is doing. Patients who get their mental health care from one office and their AUD treatment from another can receive conflicting advice or have side effects misattributed. Integrated dual-diagnosis programs do this naturally; otherwise the patient often needs to be the bridge between providers.

Mood monitoring during Lodonak treatment deserves special attention. A minority of patients experience worsened mood on naltrexone, possibly related to endorphin receptor blockade affecting mood circuits. If new or worsening depression appears during treatment, contact the provider promptly. The medication can be stopped if needed.

One of the most distinctive considerations with Lodonak is what happens if you need opioid pain relief while on the medication. Because naltrexone blocks mu-opioid receptors, standard opioid analgesics simply do not work. This creates real problems in emergency situations - severe trauma, sudden surgery, kidney stones, severe cancer pain - where opioids would normally be the first-line treatment.

Telling emergency staff about Lodonak

Always inform emergency medical staff that you are taking naltrexone. The information directly affects their treatment decisions. Carry a medical alert card or wear a medical alert bracelet noting "naltrexone (Lodonak) - mu-opioid antagonist." Both the medication name and the mechanism note matter for emergency staff who may not be familiar with naltrexone specifically.

If you are unconscious or unable to communicate, the alert bracelet may be the only way emergency staff know to adjust pain management strategy. This is one situation where the inconvenience of wearing identification is genuinely worth it.

How emergency teams handle pain on naltrexone

The clinical approach depends on the urgency. For minor injuries with manageable pain, non-opioid medications often suffice. For severe trauma or major surgery, regional anesthesia and high-dose opioid strategies under close monitoring may be needed. Many anesthesiologists and emergency physicians have encountered naltrexone patients before and have established protocols.

Planning for predictable medical events

For planned procedures, the simplest approach is to stop Lodonak ahead of time. A 3-7 day washout before elective surgery allows opioid analgesics to work normally during recovery. After healing, the medication can be resumed. This is discussed in more detail in the surgery section.

For unpredictable emergencies, planning means having the medical alert visible and having had at least one conversation with your AUD treatment provider about emergency scenarios - so you know what to communicate and what to ask for.

Planned surgery on Lodonak requires careful coordination between the addiction medicine provider, the surgeon, and the anesthesiology team. For most elective procedures, the simplest approach is to stop Lodonak in advance - allowing opioid analgesics to work normally during recovery, then resuming the medication once healing is complete. Emergency surgery is more complex but still manageable with the right communication.

The basic rule for elective surgery

Tell every member of the surgical team: surgeon, anesthesiologist, pre-op nursing, recovery nursing. The information directly affects medication choices throughout the perioperative period. Many hospitals have specific protocols for patients on naltrexone - some will not perform certain elective procedures unless the medication has been held for the appropriate window.

Pre-surgery timeline

The post-operative period deserves particular attention. Patients restarting Lodonak after surgery face the same opioid washout requirement as initial naltrexone treatment - 7 to 14 days off all opioids before the first naltrexone dose. Restarting too early risks precipitated withdrawal.

Emergency surgery

If emergency surgery cannot be delayed for naltrexone washout, the anesthesia and pain teams have several options. Regional anesthesia (epidural, spinal, nerve blocks) avoids the need for systemic opioids entirely. High-dose opioids can sometimes overcome receptor blockade with careful titration and monitoring. Non-opioid analgesics like NSAIDs, acetaminophen, and ketamine can manage moderate pain.

For these patients, intensive monitoring during the perioperative period is essential. When Lodonak eventually clears and receptors become free again, normal opioid doses can suddenly cause much more sedation and respiratory depression than expected. The transition period requires vigilance.

Non-opioid pain strategies

For minor procedures - dental work, dermatology, minor outpatient surgery - non-opioid pain management is often sufficient and Lodonak does not need to be stopped. NSAIDs (ibuprofen, naproxen) work normally on Lodonak. So does acetaminophen, local anesthetics, and most regional blocks. This avoids the disruption of stopping AUD treatment for minor reasons.

Lodonak has a relatively clean interaction profile compared to many psychiatric medications. The most clinically significant interactions involve opioids (obviously) and a few specific other drug classes. Pre-treatment medication review is straightforward but important, and ongoing vigilance about new prescriptions matters throughout treatment.

Major interactions to know about

The opioid interactions are the central concern. This includes prescription opioids, over-the-counter cough preparations containing codeine or dextromethorphan in some formulations, illicit opioids, and even some herbal products. If unsure whether a medication contains opioid activity, ask the pharmacist before taking.

Generally safe combinations

Most psychiatric medications can be used safely with Lodonak. SSRIs, SNRIs, mood stabilisers (lithium, lamotrigine), and most antipsychotics have no significant interaction. Most antihypertensives, antidiabetics, and statins also coexist with Lodonak without problems. This makes naltrexone considerably easier to use in dual-diagnosis patients than some other addiction medications.

The category that requires more care is hepatotoxic medications. Acetaminophen at standard doses is fine, but high or chronic doses combined with Lodonak warrant closer LFT monitoring. Similarly for isoniazid (TB treatment), methotrexate, and a few others.

Practical management

Tell every new prescriber that you take naltrexone. Mention it during pharmacy interactions, dental visits, urgent care, emergency departments. Most providers know about the interactions but they can only adjust if they know you are on the medication. A wallet card listing Lodonak as a current medication makes these conversations easy.

The most common medication comparison patients face for AUD is between Lodonak (naltrexone) and disulfiram (Antabuse, Carnotol). These two FDA-approved AUD medications work through completely different mechanisms and suit different patient profiles. Understanding the difference is essential for making the right treatment choice.

The mechanism difference

Naltrexone is an anti-craving medication. It blocks the mu-opioid receptors that normally release endorphins when alcohol is consumed - the chemical pathway that makes drinking rewarding. With Lodonak, alcohol becomes less interesting; the satisfaction is removed. The medication does not prevent drinking; it just removes the reward.

Disulfiram is an aversive medication. It blocks the ALDH2 enzyme, so if alcohol is consumed, acetaldehyde accumulates and produces severe physical symptoms - flushing, vomiting, tachycardia, headache. The medication deters drinking through threat of unpleasant consequence, not through any direct effect on craving or reward.

Side-by-side comparison

Choosing between them

Lodonak fits patients who experience strong cravings or reward from alcohol and want to reduce that. It also fits patients who want flexibility - abstinence is good but moderation may also be acceptable. The Sinclair Method (covered separately) particularly suits patients who can plan their drinking and want a gradual extinction approach.

Disulfiram fits patients who need an external deterrent against impulsive drinking. The classic profile is "I can be sober for stretches but I keep slipping after one drink." For these patients, the threat of severe reaction provides a hard stop that craving reduction cannot. Disulfiram patients must commit fully to abstinence and accept the safety requirements around hidden alcohol sources.

Many patients try one and switch to the other. The mechanisms are so different that response varies significantly. A failure on naltrexone does not predict failure on disulfiram, and vice versa.

Acamprosate (Campral and other brands) is the third FDA-approved medication for AUD. It works by modulating glutamate and GABA neurotransmission to reduce the prolonged withdrawal-related discomfort that drives relapse. This is yet another mechanism - completely different from naltrexone's anti-reward approach and disulfiram's aversive approach.

The mechanism difference

Naltrexone (Lodonak) acts at the moment of drinking - removing the reward when alcohol is consumed. It is most useful when craving is driven by anticipation of reward.

Acamprosate acts during recovery - helping the brain heal from the prolonged neurochemical disruption of chronic alcohol use. It is most useful when craving is driven by ongoing discomfort, sleep problems, anxiety, and "everything feels wrong" sensations during early sobriety. The neurochemistry it targets takes weeks to months to normalise.

Side-by-side comparison

Which fits which patient

Lodonak fits patients whose AUD includes strong reward-seeking - "I crave that feeling I get when drinking." It also fits patients who want flexibility about reduction versus abstinence, and patients who prefer once-daily dosing over three-times-daily.

Acamprosate fits patients who have completed detoxification and are in early recovery struggling with post-acute withdrawal symptoms - poor sleep, anxiety, restlessness, "feeling off" - that drive return to drinking. It is also the preferred choice for patients with liver concerns where naltrexone is risky and disulfiram impossible.

Can they be combined?

Yes. Naltrexone and acamprosate have complementary mechanisms - one removes the moment-of-drinking reward, the other reduces the chronic discomfort of recovery. Some clinical guidelines support combining them in specific patient profiles. The COMBINE Study examined this combination among other treatment combinations and found benefit, though not dramatically more than each medication alone.

Naltrexone is available under several brand names across the world: ReVia (the original Western brand), Vivitrol (the extended-release injection), Lodonak (Macleods, India), Naltima (Cipla, India), Nodict (Sun Pharma, India), and generic naltrexone in many markets. All contain the same active ingredient at the same standard doses. The choice between brands typically comes down to availability and cost rather than therapeutic difference.

Major naltrexone brands

Bioequivalence: the key point

All branded versions of oral naltrexone must demonstrate bioequivalence to reference naltrexone before being approved. This means they produce the same blood levels in the body. The clinical effect, side effects, drug interactions, and contraindications are identical across brands. The drug class is the same; the active ingredient is the same; the dose is the same.

When to choose which brand

For most patients globally, Lodonak or other Indian generics provide the practical pathway - affordable, available through pharmacies and online sources, identical clinical effect to branded ReVia. Patients in markets where Lodonak is readily available rarely have reason to seek out more expensive alternatives.

Patients in the United States with good insurance coverage often receive whatever generic naltrexone the pharmacy stocks, or branded ReVia if specifically prescribed. Vivitrol is the choice when adherence is the primary concern - the monthly injection removes daily dosing decisions entirely.

Switching between oral brands is straightforward: same dose, no washout, simply transition from one product to another at next refill. The body cannot tell the difference between oral naltrexone brands.

The single most important safety warning for Lodonak in the context of opioid use disorder is what happens after the medication is stopped. Tolerance to opioids drops dramatically during naltrexone treatment. If patients relapse to opioid use after stopping Lodonak, they face a significantly elevated risk of fatal overdose - because the dose they previously tolerated can now be lethal.

The clinical reality

Overdose deaths after stopping naltrexone treatment have been documented in multiple studies. The risk is highest in the first few weeks after discontinuation, when tolerance is at its lowest and when patients may be psychologically vulnerable to relapse. This pattern is one reason buprenorphine and methadone are often preferred over naltrexone for severe OUD - they do not produce this discontinuation-related overdose vulnerability.

The risk applies to any stopping of Lodonak: planned discontinuation, missed doses leading to gaps, switching to other treatments, or simply forgetting refills. Anyone who has been on naltrexone for OUD must understand this risk before stopping or considering relapse.

Risk reduction strategies

The most effective protection is to not stop Lodonak abruptly. If discontinuation is planned, coordinate it with intensive recovery support: increased counseling frequency, family involvement, restricted access to opioids, and clear contingency plans for if cravings appear. The first month after stopping is the period of highest risk.

If relapse to opioid use occurs after stopping Lodonak, treat it as a medical emergency requiring immediate evaluation. Naloxone (the opioid overdose reversal medication) should be readily available - in the home, with family members, and the patient and family should know how to use it. Naloxone is available without prescription in many regions.

Patients themselves need to understand and remember this risk. The intuitive sense that "I used X amount before, I can use X amount now" is dangerously wrong after months of Lodonak. The same X is far more dangerous than it was before treatment.

Most patients on Lodonak will eventually stop the medication - whether due to completed treatment, side effects, life circumstances, or pregnancy planning. The pharmacology of naltrexone makes stopping relatively straightforward compared to disulfiram (1-3 day washout versus 7-14 days). However, the implications of stopping differ dramatically depending on whether treatment is for AUD or OUD, and on what plans exist for ongoing recovery support.

When stopping is appropriate

There is no single right duration of Lodonak treatment. Some patients use it for a few months during early recovery, then transition to behavioral approaches alone. Others remain on it for years. The duration of treatment depends on factors including the severity of the original substance use disorder, how stable the patient is in recovery, presence of co-occurring conditions, and the patient's own preference about continuing pharmacotherapy.

How to stop

Naltrexone does not need to be tapered. There is no withdrawal syndrome from stopping. The receptor blockade simply lifts as the medication clears the system over 1 to 3 days. This is one of the easiest medications to stop pharmacologically.

The challenges of stopping are not pharmacological but behavioral. The medication has been providing some level of protection against drinking or opioid use; once stopped, that protection is gone. The success of stopping depends entirely on whether other recovery supports are in place to fill the gap.

Planning the stop

Before stopping, ensure adequate recovery infrastructure is in place: regular counseling sessions, engaged support network, identified high-risk situations and coping plans, and clear contingencies for if cravings reappear. The first weeks after stopping deserve increased rather than decreased treatment intensity for many patients.

If stopping for OUD treatment specifically, the post-discontinuation opioid sensitivity warning becomes critical. See the dedicated section on this topic. Have naloxone available in the home, and ensure family members know how to use it and recognise overdose.

Missing a dose of Lodonak is not an emergency. Naltrexone's pharmacology forgives short gaps - the active metabolite continues to occupy receptors for some time after the last dose. However, repeated missed doses or sustained gaps undermine the treatment, and for OUD specifically, gaps can create relapse risk. Understanding what to do when a dose is missed helps prevent both unnecessary panic and casual non-adherence.

What to do

The mechanics are straightforward but the underlying issue often is not. Missing one dose occasionally is human. Missing several over a week is a signal worth examining. Why is it happening? Schedule problems? Pill-management issues? Ambivalence about being on medication? Each underlying cause has a different solution.

Why missed doses matter differently for AUD vs OUD

For AUD treatment, missing a dose has a relatively small immediate effect. Naltrexone's protective effect builds over weeks of consistent dosing; one missed day does not undo that. The risk is gradual undermining of the treatment if missed doses become a pattern.

For OUD treatment, the calculation is different. A patient who misses doses and then encounters opportunity for opioid use faces immediate relapse risk - the receptor blockade is weaker than usual. Adherence support for OUD patients is more important than for AUD patients.

Common scenarios

Realised at lunchtime that morning dose was forgotten: Take it now. Resume normal schedule tomorrow. One day with slightly later dosing is not significant.

Realised at bedtime: Take it before bed. May affect sleep slightly but better than skipping. Resume normal morning schedule next day.

Realised next morning that yesterday was missed: Take today's dose at normal time only. Do not take two doses. Continue normally.

Missed multiple days in a row: Resume daily dose at next opportunity. Contact your provider to discuss the gap - especially important for OUD treatment where extended gaps can create relapse vulnerability.

Preventing missed doses

The strategies that work for medication adherence in general work for Lodonak. Pairing the dose with a daily routine (breakfast, brushing teeth, morning coffee) creates an automatic prompt. A weekly pill organiser provides visual confirmation each day. Phone reminders help during early treatment when the habit is still forming. Family or partner involvement creates external accountability.

If you have been on Lodonak for OUD and missed doses are happening regularly, the underlying issue may warrant switching to Vivitrol (the monthly injection). The medication is the same molecule but the dosing schedule is built around the patient who cannot reliably take daily medication.

Lodonak is a stable medication that does not require refrigeration or special handling. Standard pharmaceutical storage applies. This section covers practical guidance for storing the medication at home, traveling with it, and handling expiration and disposal.

Storage conditions

Store Lodonak at room temperature - between 15 and 30 degrees Celsius (59 to 86 degrees Fahrenheit). Avoid direct sunlight, which can degrade the medication over time. Avoid humid environments; the bathroom is generally not a good storage location because of shower humidity and temperature fluctuations.

Keep the medication in its original container with the label intact. This protects against light and humidity, preserves the expiration date information, and makes the medication easy to identify in emergencies. Keep out of reach of children and others who should not access the medication.

Traveling with Lodonak

Carry Lodonak in your original container with the prescription label visible. This avoids customs and security questions about identifying the medication. Bring a copy of your prescription or a brief doctor's letter explaining what the medication is for - particularly useful for international travel.

Always pack Lodonak in your carry-on luggage rather than checked baggage. Checked bags can be lost, delayed, or exposed to temperature extremes in cargo holds. Bring 25-50% more medication than you need for the trip duration to cover unexpected delays.

Most countries allow personal-use prescription medications. The documentation matters mainly for unusual situations: questioned at customs, lost luggage requiring local pharmacy refill, or medical emergency abroad where the treating provider needs to know your medications.

Expiration and disposal

Lodonak tablets typically have a 2-3 year shelf life when stored properly. Check the expiration date on the package before each refill. Do not use expired tablets - potency may decline. Discard expired medication promptly.

For disposal, return unused Lodonak to a pharmacy or medication take-back program. Do not flush down the toilet (environmental concerns). Do not throw in regular trash where children or pets could access. Many pharmacies have medication disposal programs for exactly this purpose.